A paradigm shift in multiple myeloma management emerges from the MajesTEC-3 phase 3 trial, which demonstrates that teclistamab—a bispecific antibody targeting B-cell maturation antigen and CD3—delivers substantial clinical benefits when administered earlier in treatment sequences. The landmark study, published in The New England Journal of Medicine, enrolled 740 patients with one to three prior lines of therapy and randomized them to receive either teclistamab or standard investigator’s choice treatments.
Teclistamab-treated patients achieved a median progression-free survival of 11.3 months compared with 4.0 months in the standard care arm, representing a significant 70% reduction in disease progression or death risk. Overall response rates favored teclistamab at 61.3% versus 41.9%, with complete response rates reaching 26.5% compared with 10.2%. These findings suggest moving advanced bispecific antibodies to earlier treatment lines may optimize patient outcomes and extend disease control periods.
Read the full article on GMJ Newsroom.
Was this article helpful?
